Gastroenterology

HBV Treatment: Viral Resistance
and Clinical Implications

This CME activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME activities may not contain the most up-to-date information available.

Click here to view our current activities in Gastroenterology.

HBV Treatment: Viral Resistance and Clinical Implications

View On-Demand Webcast

Dear Colleague,

Hepatitis B virus (HBV) infection is a global health issue responsible for an estimated 1 million deaths annually, and more than 4 million new cases are reported each year. The nature of the HBV lifecycle, which allows for chronic infection and frequent resistance mutations, makes treatment an ongoing challenge that requires a strategic, long-term approach. Therefore, it is imperative that physicians who treat HBV-infected patients be prepared to assess the value of new therapeutic agents as they become available and appropriately integrate them into daily practice.

HBV Treatment: Viral Resistance and Clinical Implications, a required component of the 12-month Advanced Certificate Program in the Management of Chronic Hepatitis B, is designed to build your mastery of anti-HBV treatment strategies in the context of emerging resistance. This webcast focuses on the nucleotide/nucleoside analogs, which complement short-term treatment with peginterferon/interferon alfa through distinct mechanisms of action that interrupt HBV replication. The goals of the curriculum are to provide an understanding of HBV replication and resistance mutations at the molecular level, and bring you up-to-date research on treatment efficacy and emerging resistance patterns.

Thank you for taking part in this educational activity. I hope that you find it informative and useful in your clinical practice.

Sincerely,

ADVANCED CERTIFICATE PROGRAM CO-CHAIR/WEBCAST MODERATOR
Adrian M. Di Bisceglie, MD, FACP Professor of Internal Medicine Chief of Hepatology Saint Louis University School of Medicine St. Louis, Missouri
WEBCAST CHAIR
Mark S. Sulkowski, MD Associate Professor of Medicine Department of Medicine Division of Infectious Diseases The Johns Hopkins University School of Medicine Baltimore, Maryland
FACULTY
Brent E. Korba, PhD Professor Department of Microbiology & Immunology Georgetown University Medical Center Rockville, Maryland Chloe L. Thio, MD Assistant Professor of Medicine Department of Medicine Division of Infectious Diseases The Johns Hopkins University School of Medicine Baltimore, Maryland

top

TARGET AUDIENCE

This activity is designed for gastroenterologists, hepatologists, and other clinicians who care for patients with hepatitis B infection or those at increased risk for acquiring the infection.

ACTIVITY GOAL

The goal of this activity is to examine current and emerging strategies for diagnosing and treating patients infected with HBV.

LEARNING OBJECTIVES

Determine appropriate anti-HBV treatment regimens for infected patients by correlating the molecular biology and replication cycle of HBV to resistance development mechanisms in currently available agents.
Identify HBV resistance/cross-resistance patterns inherent in approved agents and adjust treatment regimens accordingly to produce optimal outcomes in HBV-infected patients.
Evaluate the clinical implications of drug resistance for each specific anti-HBV agent in order to devise successful long-term treatment plans for anti-HBV infected patients.
Incorporate proactive prescribing and monitoring strategies to help prevent or reduce the emergence of resistance into individualized anti-HBV treatment plans for infected patients.

top

CME INFORMATION

Statement of Accreditation

Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Projects In Knowledge designates this educational activity for a maximum of 1.0 Category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

This activity is planned and implemented as an independent CME activity in accordance with the ACCME Essential Areas and Policies.

CE INFORMATION—NURSES

This activity has been approved by the American Association of Critical-Care Nurses (ACCN) for 1.0 contact hour. Provider #00012705.

Contract for Mutual Responsibility in CME/CE
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.

top

DISCLOSURE INFORMATION

The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.

For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).

Adrian M. Di Bisceglie, MD, FACP, has received grant/research support from Gilead Sciences, Inc, Intermune Inc, Roche Pharmaceuticals, Schering-Plough Corporation, SciClone Pharmceuticals, and Vertex Pharmaceuticals Incorporated; is a consultant for Abbott Laboratories, Bristol-Myers Squibb Company, Chiron Corporation, InterMune Inc, and SciClone Pharmaceuticals; is on the speakers bureau of Schering-Plough Corporation; is a member of advisory boards for Idenix Pharmaceuticals, Inc, MDS Nordion, Novartis Pharmaceuticals Corporation, Roche Pharmaceuticals, and Vertex Pharmaceuticals Incorporated; and is a member of the Data Safety Monitoring Board for Schering-Plough Corporation. Dr. Di Bisceglie has disclosed that he will not reference unlabeled/unapproved uses of drugs or products in his presentation.

Brent E. Korba, PhD, is a consultant for Bukwang Pharmaceuticals, Inc and Spring Bank Technologies; is on the advisory board of Immugen Pharmaceuticals, Inc and SomaGenics, Inc; and has an ownership interest in Pharmasset, Inc. Dr. Korba has disclosed that he will not reference unlabeled/unapproved uses of drugs or products in his presentation.

Mark S. Sulkowski, MD, has received grant/research support from Akros Pharma Inc, Human Genome Sciences, Idenix Pharmaceuticals Inc, Roche Pharmaceuticals, Schering-Plough Corporation, Valeant Pharmaceuticals International, and Vertex Pharmaceuticals Incorporated; is on the advisory board of Boehringer-Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb Company, Human Genome Sciences, Ortho Biotech Products, LP, Roche Pharmaceuticals, Schering-Plough Corporation, and Valeant Pharmaceuticals International; and is on the speakers bureau of Abbott Laboratories, Ortho Biotech Products, LP, Roche Pharmaceuticals, and Schering-Plough Corporation. Dr. Sulkowski has disclosed that he will not reference unlabeled/unapproved uses of drugs or products in his presentation.

Chloe L. Thio, MD, has an ownership interest in Gilead Sciences, Inc. Dr. Thio has disclosed that she will not reference unlabeled/unapproved uses of drugs or products in her presentation.

Peer Reviewer has disclosed no significant relationships.

Projects In Knowledge's staff members have no significant relationships to disclose.

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

This independent CME/CE activity is supported by an educational grant from
Bristol-Myers Squibb Company.

top

1719